[go: up one dir, main page]

BR0012478A - Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos - Google Patents

Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos

Info

Publication number
BR0012478A
BR0012478A BR0012478-8A BR0012478A BR0012478A BR 0012478 A BR0012478 A BR 0012478A BR 0012478 A BR0012478 A BR 0012478A BR 0012478 A BR0012478 A BR 0012478A
Authority
BR
Brazil
Prior art keywords
same
composition containing
pharmaceutical preparation
aminothiazole derivatives
derivatives
Prior art date
Application number
BR0012478-8A
Other languages
English (en)
Other versions
BR0012478B1 (pt
Inventor
Evelyne Fontaine
Michel Geslin
Danielle Gully
Antoine Pradines
Pierre Roger
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of BR0012478A publication Critical patent/BR0012478A/pt
Publication of BR0012478B1 publication Critical patent/BR0012478B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)

Abstract

Patente de Invenção: "DERIVADOS DE AMINOTIAZóIS, SUA PREPARAçãO E COMPOSIçõES FARMACêUTICAS CONTENDO OS MESMOS". A invenção refere-se a compostos de fórmula (I) em que: R~ 1~, R~ 2~, R~ 3~, R~ 4~, R~ 5~, R~ 6~, e R~ 7~ são como definidos na reivindicação 1. Os compostos referidos têm uma afinidade para receptores de C R F.
BRPI0012478-8B1A 1999-07-15 2000-07-11 Derivados de aminotiazóis, composições farmacêuticas compreendendo os mesmos, bem como seu uso e processo de preparação BR0012478B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9909144A FR2796380B3 (fr) 1999-07-15 1999-07-15 Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
PCT/FR2000/001995 WO2001005776A1 (fr) 1999-07-15 2000-07-11 Derives d'aminothiazole et leur utilisation comme ligands des recepteurs crf

Publications (2)

Publication Number Publication Date
BR0012478A true BR0012478A (pt) 2002-04-02
BR0012478B1 BR0012478B1 (pt) 2013-10-15

Family

ID=9548107

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0012478-8B1A BR0012478B1 (pt) 1999-07-15 2000-07-11 Derivados de aminotiazóis, composições farmacêuticas compreendendo os mesmos, bem como seu uso e processo de preparação

Country Status (36)

Country Link
US (2) US6586456B1 (pt)
EP (1) EP1200419B1 (pt)
JP (1) JP4949582B2 (pt)
KR (1) KR100707320B1 (pt)
CN (1) CN1167692C (pt)
AR (1) AR024747A1 (pt)
AT (1) ATE264315T1 (pt)
AU (1) AU772683B2 (pt)
BR (1) BR0012478B1 (pt)
CA (1) CA2378792C (pt)
CO (1) CO5200792A1 (pt)
CZ (1) CZ300937B6 (pt)
DE (1) DE60009911T2 (pt)
DK (1) DK1200419T3 (pt)
EA (1) EA005159B1 (pt)
EE (1) EE05004B1 (pt)
ES (1) ES2220504T3 (pt)
FR (1) FR2796380B3 (pt)
HK (1) HK1045692B (pt)
HU (1) HU229069B1 (pt)
IL (2) IL147282A0 (pt)
IS (1) IS2314B (pt)
ME (1) MEP26608A (pt)
MX (1) MXPA02000545A (pt)
NO (1) NO324352B1 (pt)
NZ (1) NZ516397A (pt)
PL (1) PL206515B1 (pt)
PT (1) PT1200419E (pt)
RS (1) RS50443B (pt)
SI (1) SI1200419T1 (pt)
SK (1) SK287069B6 (pt)
TR (1) TR200200125T2 (pt)
TW (1) TWI278453B (pt)
UA (1) UA73125C2 (pt)
WO (1) WO2001005776A1 (pt)
ZA (1) ZA200200221B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1320365A4 (en) * 2000-09-21 2004-03-17 Bristol Myers Squibb Co SUBSTITUTED AZOLE DERIVATIVES AS AN INHIBITOR OF THE CORTICOTROPIN RELEASE FACTOR
WO2003015777A1 (en) * 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
AU2002334772A1 (en) 2001-10-12 2003-04-28 Duke University Methods for image analysis of high-density synthetic dna microarrays
EP2527446A1 (en) 2004-06-03 2012-11-28 Athlomics Pty Ltd Agents and methods for diagnosing stress
MX2007001727A (es) * 2004-08-13 2007-04-20 Genentech Inc Compuestos a base de 2-amido-tiazol que exhiben actividad inhibidora de enzima que utiliza atp y composiciones y usos de los mismos.
EP1834641A1 (en) * 2006-03-16 2007-09-19 Sanofi-Aventis Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
HUP0900267A2 (en) * 2009-04-30 2011-03-28 Sanofi Aventis Process for preparing of thiazole amines and intermediates thereof
EP2841068B8 (en) * 2012-04-23 2019-03-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Crhr1 antagonists for use in the treatment of patients having crh overactivity
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
SI3096756T1 (sl) 2014-01-21 2024-09-30 Neurocrine Biosciences, Inc. CRF1 receptorski antagonisti za zdravljenje kongenitalne adrenalne hiperplazije
BR112021010847A2 (pt) * 2018-12-07 2021-09-08 Neurocrine Biosciences Inc. Antagonista de receptor de crf1, formulações farmacêuticas e formas sólidas das mesmas para o tratamento de hiperplasia adrenal congênita
JP7532328B2 (ja) * 2018-12-07 2024-08-13 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
CN114502162A (zh) * 2019-09-27 2022-05-13 纽罗克里生物科学有限公司 Crf受体拮抗剂及使用方法
US20230255942A1 (en) 2020-06-10 2023-08-17 Neurocrine Biosciences, Inc. Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692893B1 (fr) * 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
FR2714059B1 (fr) * 1993-12-21 1996-03-08 Sanofi Elf Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
FR2735777B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2754258B1 (fr) * 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
HUP0202387A2 (hu) 2002-11-28
AU6452100A (en) 2001-02-05
CA2378792A1 (en) 2001-01-25
YU1302A (sh) 2005-03-15
FR2796380B3 (fr) 2001-08-17
NO20020155D0 (no) 2002-01-11
NO20020155L (no) 2002-03-15
EE05004B1 (et) 2008-04-15
IL147282A (en) 2008-04-13
US8420679B2 (en) 2013-04-16
DE60009911T2 (de) 2005-03-10
CN1167692C (zh) 2004-09-22
SK287069B6 (sk) 2009-11-05
NZ516397A (en) 2004-01-30
US6586456B1 (en) 2003-07-01
IL147282A0 (en) 2002-08-14
HK1045692A1 (en) 2002-12-06
UA73125C2 (uk) 2005-06-15
EA005159B1 (ru) 2004-12-30
EA200101234A1 (ru) 2002-08-29
ATE264315T1 (de) 2004-04-15
TWI278453B (en) 2007-04-11
JP4949582B2 (ja) 2012-06-13
FR2796380A1 (fr) 2001-01-19
HU229069B1 (en) 2013-07-29
AU772683B2 (en) 2004-05-06
EP1200419A1 (fr) 2002-05-02
HUP0202387A3 (en) 2004-12-28
EP1200419B1 (fr) 2004-04-14
IS6219A (is) 2002-01-03
US20070281919A1 (en) 2007-12-06
BR0012478B1 (pt) 2013-10-15
PT1200419E (pt) 2004-07-30
IS2314B (is) 2007-11-15
EE200200022A (et) 2003-04-15
CZ300937B6 (cs) 2009-09-16
JP2003505380A (ja) 2003-02-12
PL352901A1 (en) 2003-09-22
SK382002A3 (en) 2002-07-02
SI1200419T1 (en) 2004-08-31
CZ2002137A3 (cs) 2002-04-17
ZA200200221B (en) 2003-04-30
NO324352B1 (no) 2007-09-24
CO5200792A1 (es) 2002-09-27
DE60009911D1 (de) 2004-05-19
AR024747A1 (es) 2002-10-23
PL206515B1 (pl) 2010-08-31
ES2220504T3 (es) 2004-12-16
DK1200419T3 (da) 2004-07-19
WO2001005776A1 (fr) 2001-01-25
TR200200125T2 (tr) 2002-09-23
CN1370154A (zh) 2002-09-18
KR100707320B1 (ko) 2007-04-13
RS50443B (sr) 2010-03-02
MEP26608A (en) 2010-06-10
HK1045692B (zh) 2004-11-26
KR20020015373A (ko) 2002-02-27
MXPA02000545A (es) 2002-07-30
CA2378792C (en) 2009-11-10

Similar Documents

Publication Publication Date Title
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0108395A (pt) Derivados de pirrolopirimidinona, processos de preparação e uso
BR0108871A (pt) Composto, processo de preparação de compostos, e, composição farmacêutica
BR9707064A (pt) Novos derivados 19-nor-pregneno
BR0012478A (pt) Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
BR0115580A (pt) Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
YU56995A (sh) Soli derivata indola
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0507877A (pt) derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BRPI0510273A (pt) derivados de tetraazabenzo[e]azuleno e análogos destes
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BR0309106A (pt) Derivados de terfenila, seu preparo, as composições farmacêuticas que os contêm
BR9812653A (pt) Derivados de carboxamidotiazóis, sua preparação, as composições farmacêuticas que os contêm
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
BR0316532A (pt) Composições farmacêuticas compreendendo, um composto de droga básico, respectivamente um ácido, um tensoativo e um ácido solúvel em água fisiologicamente tolerável, respectivamente, uma base
BR0113989A (pt) Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
UY29007A1 (es) Derivados de 2-carbamida-4-feniltiazol, su preparacinn, y su aplicacinn en terapcutica
BR0310077A (pt) Novos compostos e sua utilização
PT1254134E (pt) Derivados de 1,3-di-hidro-2h-indol-2-ona e sua utilizacao como ligandos para os receptores v1b ou v1b e v1a da arginina-vasopressina

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS (FR)

Free format text: ALTERADO DE: SANOFI-SYNTHELABO

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/10/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)